Advertisement
Organisation › Details
Nexstim Oyj
Nexstim is a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain. Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBT® system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBT® system for this important indication during H1 2018. The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. *
Start | 2015-07-18 existent | |
Group | Nexstim (Group) | |
Industry | medical device | |
Person | Jamieson, Martin (Nexstim 201712 CEO) | |
Region | Helsinki | |
Country | Finland | |
Street | 9 B Elimäenkatu | |
City | 00510 Helsinki | |
Tel | +358-9-2727-1710 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Nexstim Oyj. (12/1/17). "Press Release: Nexstim Plc Appoints Steve Beller as Vice President and General Manager, North America". Helsinki. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Nexstim (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top